|Bid||149.51 x 100|
|Ask||200.00 x 200|
|Day's Range||161.45 - 165.79|
|52 Week Range||102.45 - 173.01|
|PE Ratio (TTM)||56.66|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.